亞太藥業(002370.SZ):簽署拆遷補償協議 拆遷補償款總額約2.66億元
格隆匯 12 月 25日丨亞太藥業(002370.SZ)公佈,公司於2020年12月25日召開的第六屆董事會第二十六次會議審議通過了《關於簽署拆遷補償協議的議案》,同意紹興市柯橋區中心城建設投資開發有限公司以現金方式對公司柯橋廠區房屋拆遷進行補償,拆遷補償款總額為265,969,462.00元。
隨着紹興濱海新城“現代醫藥製劑一期、二期項目”片劑(含青黴素類)、硬膠囊劑(含頭孢菌素類、青黴素類)、粉針劑(頭孢菌素類)、凍乾粉針劑製劑生產線陸續通過GMP認證或現場檢查,公司生產基地已轉移至紹興濱海新城,此次拆遷不會影響公司正常生產經營。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.